Global Erbitux Market is Segmented By Dosage Type (Injection, Tablet, Other), By End-User (Hospital Pharmacy, Retail Pharmacies, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029
Market Overview
The global erbitux market size is estimated to reach at a high CAGR during the forecast period 2022-2029
Erbitux is approved to treat patients with colorectal cancer that has spread to other parts of the body. The generic name for the brand-name drug Erbitux is Cetuximab. When referring to the generic drug name Cetuximab, health care professionals may use the trade name Erbitux or another name C225 in some cases.
Market Dynamics
The factor driving the global Erbitux market is the growing demand for the treatment of metastatic colorectal cancer and head and neck cancer.
The growing demand for the treatment of metastatic colorectal cancer and head and neck cancer is expected to drive the market growth
Colorectal cancer (CRC) is one of the world's three deadliest cancers, with a poor prognosis and a high rate of metastasis. However, the early symptoms of CRC are subtle, and approximately 15–25 per cent of patients with CRC were diagnosed as an advanced stage during the initial check-up. As a result, half of all patients with metastatic colorectal cancer (mCRC) are inoperable, resulting in recurrence and metastasis after treatment.
On 29th September 2021, the FDA approved Erbitux in combination with Braftovi (encorafenib) for pre-treated BRAF V600E-mutant metastatic colorectal cancer (CRC). The approval was based on findings from the phase 3 BEACON CRC trial, which revealed that the drug combination resulted in an average overall survival rate of 8.4 months compared to 5.4 months in the control group of patients who received irinotecan in combination with Erbitux or FOLFIRI (a chemotherapy combination used to treat metastatic colorectal cancer) in combination with Erbitux. It's a significant advancement because this cancer type is extremely aggressive once it spreads, and all other treatments have failed. Patients whose tumors contain the BRAF V600E mutation have a poor prognosis. After unsuccessful initial therapy, the median survival time is only four to six months, and they frequently have unpleasant symptoms such as abdominal swelling or bowel blockage. The trial demonstrated that this combination therapy extends people's lives, delays the onset of these symptoms, and improves their quality of life.
Side-effects of the drug are expected to hamper its market growth
Severe allergic reactions are a serious side effect of Erbitux. Allergic reactions are uncommon, but they can be fatal. Low blood pressure, shock, loss of consciousness, and a heart attack are all possible symptoms. Severe allergic reactions can occur at any point during treatment, but they are most common during the first dose. People who have a history of tick bites, a red meat allergy, or specific antibodies are at a higher risk of anaphylactic reactions. Another serious side effect of erbitux is a heart attack. Some people who received erbitux with radiation therapy or cetuximab with platinum-based chemotherapy and fluorouracil experienced heart attacks or died unexpectedly. Infusion-related reactions can also result in a heart attack. When erbitux was used in conjunction with radiation therapy, the overall incidence of late radiation toxicities (of any grade) was higher than when radiation therapy was used alone.
COVID-19 Impact Analysis
The COVID-19 pandemic had an impact on all stages of drug development, forcing many drugs development companies and clinical research organizations (CROs) to halt at least some and in many cases all their clinical trials. While pausing clinical studies is not uncommon (especially early in development), never have so many companies experienced a disruption of this magnitude at the same time. For instance, the company Merck’s Erbitux and Bavencio was impacted sequentially by COVID-19, their sales declined. Hence, COVID-19 impacted the global erbitux market growth negatively with the halt in the drug development process.
Segment Analysis
Based on dosage type, the injection segment is expected to dominate the market
Injections are a type of parenteral drug administration because they do not involve absorption in the digestive tract. This allows the medication to be absorbed more quickly and eliminates the first-pass effect. Cetuximab is available as a solution (liquid) that is infused (slowly injected) into a vein. It is administered by injection into a vein as directed by a doctor, usually once every week or every two weeks. Cetuximab is administered slowly, and the infusion lasts up to 2 hours. Hence, it is given by injection mostly. Other medications may be prescribed to help prevent serious side effects or allergic reactions. Cetuximab is frequently used in conjunction with other cancer medications and/or radiation therapy. One hour after cetuximab infusion, a patient may be given another cancer medication.
For example, on September 8th, 2021, Eli Lilly and Company received the U.S. FDA approval for ERBITUX (cetuximab injection) in combination with BRAFTOVI (encorafenib), marketed by Pfizer, Inc., for the treatment of adult patients with metastatic colorectal cancer (CRC) who have a BRAF V600E mutation as detected by an FDA-approved test after prior therapy.
Geographical Analysis
North America region accounted for the largest market share in the global Erbitux market
The increasing prevalence of colorectal cancer and the presence of key players is expected to drive the market growth in this region.
According to the American Cancer Society, in both men and women, it is the third leading cause of cancer-related deaths and the second leading cause when men and women are combined. The number of colorectal cancer cases in the United States in 2021 will be 104,270 new cases of colon cancer and 45,230 new cases of rectal cancer. It is expected to kill 52,980 people in 2021.
On July 28th, 2021, a U.S based company Flatiron Health real-world data (RWD) supported the recent FDA approval of a new dosing regimen for ERBITUX (Eli Lilly and Company's cetuximab), which can have a direct positive impact on the lives of patients with metastatic colorectal cancer (CRC) or squamous cell carcinoma of the head and neck (SCCHN).
Competitive Landscape
The global erbitux market is moderately competitive with partnerships, mergers, and recent product launches by key players. Some of the major key players in the global erbitux market are Merck, Bristol-Myers Squibb, Eli Lilly, Manus Aktteva Biopharma LLP, Hubei xinkang pharmaceutical chemical co.,ltd., Array BioPharma Inc., Wuhan Sunrise Technology Development Company Limited, Chembest Research Laboratories Limited, NKMax and Pierre Fabre.
Merck
Overview: Merck is a multinational German science and technology company. The company is headquartered in Darmstadt employs approximately 57,000 people and operates in 66 countries. The group consists of approximately 250 companies, the largest of which is Merck KGaA in Germany.
Product Portfolio: The company manufactures Erbitux 5 mg/mL solution for infusion (Cetuximab). It is supplied in vials containing 20 mL or 100 mL. Each pack contains 1 vial.
Key Development: On March 2nd, 2020, The National Medical Products Administration (NMPA) of China approved Merk’s ERBITUX (cetuximab) for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil.
Trending Topics
